Adjuvant Capital
New York City, New Yorkadjuvantcapital.com
Overview
Adjuvant Capital is a life sciences venture capital firm that invests in companies developing technologies for high-burden public health challenges in low- and middle-income countries . It focuses on neglected, high-burden, and emerging infectious diseases, maternal, newborn, and child health challenges, reproductive and sexual health and nutrition .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| VitriVax, Inc. | Oct 2025 | Series B | Lead |
| Curevo Vaccine | Mar 2025 | Series B | Co-investor |
| Memo Therapeutics AG | May 2024 | Series C Extension | Co-investor |
| LimmaTech Biologics | Feb 2024 | Series A Extension | Co-investor |
| Memo Therapeutics AG | Nov 2023 | Series C | Co-investor |
Key People
Charlie Petty
Co-Founder
Glenn Rockman
Founder and Managing Partner
Gerard Cunningham
Operating Partner
Mark Sullivan AO
Venture Partner
Michael Chang
Venture Partner
Kabeer Aziz
Partner
Abrar Haque
Investor
Giulia Balconi
Life Sciences Venture Capital
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
